Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ENGN 
enGene Holdings Inc. Common Stock (ENGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: ENGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit -12.12% | Avg. Invested days 133 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 219.20M USD | Price to earnings Ratio - | 1Y Target Price 23.36 |
Price to earnings Ratio - | 1Y Target Price 23.36 | ||
Volume (30-day avg) 2144 | Beta -0.61 | 52 Weeks Range 3.80 - 17.54 | Updated Date 03/30/2025 |
52 Weeks Range 3.80 - 17.54 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.48 |
Earnings Date
Report Date 2025-03-11 | When - | Estimate -0.3783 | Actual -0.48 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.75% | Return on Equity (TTM) -44.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 30523508 | Price to Sales(TTM) - |
Enterprise Value 30523508 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.01 | Shares Outstanding 50977600 | Shares Floating 24461582 |
Shares Outstanding 50977600 | Shares Floating 24461582 | ||
Percent Insiders 13.61 | Percent Institutions 74.73 |
Analyst Ratings
Rating 4.56 | Target Price 27 | Buy 4 | Strong Buy 5 |
Buy 4 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
enGene Holdings Inc. Common Stock
Company Overview
History and Background
enGene Holdings Inc. is a clinical-stage genetic medicines company focused on developing innovative technologies for the treatment of cancer and other diseases. Founded in 2000, the company has been developing gene delivery platforms and therapeutic candidates.
Core Business Areas
- Oncolytic Immunotherapy: Developing immunotherapies to treat various cancers.
- Gene Therapy: Creating gene therapies for a range of diseases through its proprietary gene delivery platforms.
Leadership and Structure
The leadership team consists of experienced executives in biotechnology and pharmaceuticals. The company operates with a hierarchical structure typical for biotech companies.
Top Products and Market Share
Key Offerings
- EG-70: EG-70 is enGene's lead product candidate, an investigational gene-mediated immunotherapy designed to express IL-12 locally in the tumor microenvironment for the treatment of high-risk, non-muscle invasive bladder cancer (NMIBC). The NMIBC market is competitive. Competitors include Merck (Keytruda), ImmunityBio (Anktiva), and numerous other pharmaceutical companies.
Market Dynamics
Industry Overview
The genetic medicines industry is rapidly evolving, with advancements in gene therapy and immunotherapy leading to new treatment options for previously untreatable diseases. The bladder cancer treatment market is also growing, driven by an aging population and increasing incidence rates.
Positioning
enGene aims to be a leader in gene-mediated immunotherapies. Its proprietary gene delivery platform gives it a competitive advantage.
Total Addressable Market (TAM)
The total addressable market for bladder cancer treatment is estimated to be multi-billion dollar market. enGene is positioned to capture a part of this market with its EG-70 candidate.
Upturn SWOT Analysis
Strengths
- Proprietary gene delivery platform
- Innovative approach to cancer treatment
- Experienced management team
- Focus on high unmet medical needs
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful clinical trial outcomes
- Potential regulatory hurdles
- Early stage development company
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline with new therapeutic candidates
- Positive clinical trial data for EG-70
- Advancements in gene therapy technologies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory delays
- Economic downturn impacting investment in biotechnology
Competitors and Market Share
Key Competitors
- MRK
- IMMB
Competitive Landscape
enGene faces significant competition from larger pharmaceutical companies with established products. enGene's advantage lies in its innovative gene delivery platform. enGene must focus on demonstrating superior clinical efficacy to capture significant market share.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is reflected in the advancement of its pipeline and the expansion of its intellectual property portfolio.
Future Projections: Future growth is dependent on the success of its EG-70 clinical trials and the development of other therapeutic candidates. Analyst projections are highly variable at this stage.
Recent Initiatives: Recent initiatives likely include patient enrollment in ongoing clinical trials, partnering activities, and presentations at scientific conferences.
Summary
enGene Holdings is a clinical-stage biotech company with an innovative gene delivery platform. It is working on EG-70, a product for bladder cancer. The company currently has no revenue and is reliant on clinical trials to prove the product's efficacy. enGene Holdings is dependent on securing funding. The company needs to look out for competitors already on the market.
Similar Companies
- MRK
- IMMB
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About enGene Holdings Inc. Common Stock
Exchange NASDAQ | Headquaters Montreal, QC, Canada | ||
IPO Launch date 2023-11-01 | President, CEO & Director Mr. Ronald H. W. Cooper | ||
Sector Healthcare | Industry Biotechnology | Full time employees 56 | Website https://www.engene.com |
Full time employees 56 | Website https://www.engene.com | ||
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.